CheMOnitor, an AI-supported diagnostic tool developed by the Translational Glycomics Research Group at the University of Pannonia, has earned international recognition by advancing to the second round of the prestigious EIT Jumpstarter 2025 innovation program. The program supports top European startups with strong market potential.
Led by PhD student Rebeka Török, the CheMOnitor project uses a novel glycan-based blood test combined with deep learning to predict the effectiveness of chemotherapy in lung cancer patients. The method could significantly reduce the time currently required to assess treatment effectiveness—shortening it from 3–5 months to a matter of weeks—while lowering costs and avoiding unnecessary side effects.
Launched in 2018, CheMOnitor has been built on close collaboration between the University of Pannonia, the University of Debrecen, and regional hospitals. Following successful testing on nearly 100 blood samples with over 90% accuracy, the university has filed a patent for the method. Two major international publications have since featured the findings.
As CheMOnitor progresses in the EIT program, its team will continue refining their business model with guidance from international mentors, paving the way for the technology’s market entry and broader impact on global healthcare.
Source: University of Pannonia
About the Author
